Literature DB >> 20401539

Studies in the modulation of experimental autoimmune encephalomyelitis.

Jane E Libbey1, Ikuo Tsunoda, Robert S Fujinami.   

Abstract

Experimental autoimmune encephalomyelitis (EAE), an experimental model for multiple sclerosis, can be induced through inoculation with several different central nervous system (CNS) proteins or peptides. Modulation of EAE, resulting in either protection from EAE or enhancement of EAE, can also be accomplished through either vaccination or DNA immunization with molecular mimics of self-CNS proteins. Previously published data on this method of EAE modulation will be reviewed. New data is presented, which demonstrates that EAE can also be modulated through the administration of the beta-(1,3)-D-glucan, curdlan. Dendritic cells stimulated by curdlan are involved in the differentiation of the interleukin-17 producing subset of CD4(+) T cells that are recognized effector cells in EAE. Using two different systems to study the effects of curdlan on EAE, it was found that curdlan increased the incidence of EAE and/or the severity of the disease course.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20401539      PMCID: PMC3046865          DOI: 10.1007/s11481-010-9215-x

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  44 in total

Review 1.  Can virus infections trigger autoimmune disease?

Authors:  R S Fujinami
Journal:  J Autoimmun       Date:  2001-05       Impact factor: 7.094

Review 2.  Encephalitogenic epitopes of myelin basic protein.

Authors:  R B Fritz; D E McFarlin
Journal:  Chem Immunol       Date:  1989

3.  Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway.

Authors:  H Garren; P J Ruiz; T A Watkins; P Fontoura; L T Nguyen; E R Estline; D L Hirschberg; L Steinman
Journal:  Immunity       Date:  2001-07       Impact factor: 31.745

4.  Viruses can silently prime for and trigger central nervous system autoimmune disease.

Authors:  D J Theil; I Tsunoda; F Rodriguez; J L Whitton; R S Fujinami
Journal:  J Neurovirol       Date:  2001-06       Impact factor: 2.643

5.  Enhancement of autoimmune disease using recombinant vaccinia virus encoding myelin proteolipid protein.

Authors:  L A Barnett; J L Whitton; Y Wada; R S Fujinami
Journal:  J Neuroimmunol       Date:  1993-04       Impact factor: 3.478

6.  T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis.

Authors:  S S Zamvil; D J Mitchell; A C Moore; K Kitamura; L Steinman; J B Rothbard
Journal:  Nature       Date:  1986 Nov 20-26       Impact factor: 49.962

7.  Identification of epitopes of myelin oligodendrocyte glycoprotein for the induction of experimental allergic encephalomyelitis in SJL and Biozzi AB/H mice.

Authors:  S Amor; N Groome; C Linington; M M Morris; K Dornmair; M V Gardinier; J M Matthieu; D Baker
Journal:  J Immunol       Date:  1994-11-15       Impact factor: 5.422

Review 8.  Minireview: autoimmune responses to myelin proteolipid protein.

Authors:  R A Sobel; J M Greer; V K Kuchroo
Journal:  Neurochem Res       Date:  1994-08       Impact factor: 3.996

9.  A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis.

Authors:  E S Huseby; D Liggitt; T Brabb; B Schnabel; C Ohlén; J Goverman
Journal:  J Exp Med       Date:  2001-09-03       Impact factor: 14.307

Review 10.  Potential triggers of MS.

Authors:  Jane E Libbey; Robert S Fujinami
Journal:  Results Probl Cell Differ       Date:  2010
View more
  9 in total

1.  Two discreet subsets of CD8 T cells modulate PLP(91-110) induced experimental autoimmune encephalomyelitis in HLA-DR3 transgenic mice.

Authors:  Ashutosh K Mangalam; David Luckey; Shailendra Giri; Michele Smart; Larry R Pease; Moses Rodriguez; Chella S David
Journal:  J Autoimmun       Date:  2012-03-28       Impact factor: 7.094

2.  Immunomodulation of experimental allergic encephalomyelitis by cinnamon metabolite sodium benzoate.

Authors:  Kalipada Pahan
Journal:  Immunopharmacol Immunotoxicol       Date:  2011-03-22       Impact factor: 2.730

3.  DA virus mutant H101 has altered CNS pathogenesis and causes immunosuppression.

Authors:  Matthew F Cusick; Jane E Libbey; Daniel J Doty; Robert S Fujinami
Journal:  J Neuroimmunol       Date:  2014-11-06       Impact factor: 3.478

4.  Acthar gel treatment suppresses acute exacerbations in a murine model of relapsing-remitting multiple sclerosis.

Authors:  Matthew F Cusick; Jane E Libbey; Luke Oh; Shaun Jordan; Robert S Fujinami
Journal:  Autoimmunity       Date:  2014-11-20       Impact factor: 2.815

5.  Neuroimmune pharmacological control of EAE.

Authors:  Kalipada Pahan
Journal:  J Neuroimmune Pharmacol       Date:  2010-04-23       Impact factor: 4.147

6.  Possible role of interleukin-17 in a prime/challenge model of multiple sclerosis.

Authors:  Jane E Libbey; Ikuo Tsunoda; Robert S Fujinami
Journal:  J Neurovirol       Date:  2012-09-19       Impact factor: 3.739

7.  Targeting insulin-like growth factor 1 leads to amelioration of inflammatory demyelinating disease.

Authors:  Matthew F Cusick; Jane E Libbey; Nikolaus S Trede; Robert S Fujinami
Journal:  PLoS One       Date:  2014-04-09       Impact factor: 3.240

8.  Bioinformatics Analyses Determined the Distinct CNS and Peripheral Surrogate Biomarker Candidates Between Two Mouse Models for Progressive Multiple Sclerosis.

Authors:  Seiichi Omura; Fumitaka Sato; Nicholas E Martinez; Ah-Mee Park; Mitsugu Fujita; Nikki J Kennett; Urška Cvek; Alireza Minagar; J Steven Alexander; Ikuo Tsunoda
Journal:  Front Immunol       Date:  2019-03-19       Impact factor: 7.561

9.  Curdlan, a Microbial β-Glucan, Has Contrasting Effects on Autoimmune and Viral Models of Multiple Sclerosis.

Authors:  Fumitaka Sato; Yumina Nakamura; Aoshi Katsuki; Sundar Khadka; Ijaz Ahmad; Seiichi Omura; Nicholas E Martinez; Ikuo Tsunoda
Journal:  Front Cell Infect Microbiol       Date:  2022-02-07       Impact factor: 5.293

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.